The names are impressive. The proof isn’t.

The adviser list is not a lab result

Clair has no shortage of impressive names. Its about page lists Sara Vaughn as chief medical officer and Emily Kraus and Roxana Daneshjou as advisers. Mayo independently confirms the accelerator relationship. Good. We have established that Clair joined a program. Now let’s establish that the bracelet does what Clair says.

Customers will wear the device, not the adviser list. A real relationship does not tell us how close the hormone predictions come to reference measurements, which users were excluded, or how often the model gets the answer wrong. Those answers require an experiment. An affiliation announcement will not do.

The names can stay. Publish the results.

$18 million. Show the terms.

Then comes the traction. The a16z speedrun profile credits Clair with $800,000 in direct-to-consumer revenue and $18 million in signed business-to-business contracts in less than eight weeks. The number is enormous. The terms are missing.

I challenged the contracts description in my October 14 LinkedIn post. Clair’s fundraising deck supplies its own vocabulary: “B2B device purchase MOUs” on one slide and “OUR LOIS INCLUDE” on another. Reach Capital separately described more than 100 letters of intent from fertility clinics. Contracts in the investor profile. MOUs and LOIs in the company’s deck. Before celebrating the $18 million, let’s identify what was actually signed.

The public deck blacks out the MOU count and value and the partner names. The redacted deck cannot identify these as the agreements behind the $18 million. The labels alone do not establish what is binding, cancellable, or conditional, and my allegation that the agreements were withdrawable still requires the terms. A black rectangle is not a substitute for them.

Publish the terms. Identify the agreements behind the headline, spell out the obligations, and separate money collected from interest expressed. Eighteen million dollars is a very specific number. Clair can manage an equally specific explanation.

Why I brought up Theranos

Yes, I invoke Theranos. A compelling story, impressive people, and a health breakthrough presented with more confidence than the evidence earns. That is the warning. Prestige can sell a pitch long before the product earns the customer’s trust.

That comparison does not establish that Clair fabricated data or committed the fraud proven in the Theranos case. It does establish the standard I am applying: show that the product works. I do not need access to a founder’s thoughts to reject a promise the reviewed public evidence does not substantiate.

Clair said the concentration-estimation capability already existed. It presented impressive internal metrics. It also described important validation as future work. Apparently, the breakthrough was ready before the work needed to establish it. Publish what had actually been demonstrated when the claim was made.

Why I call the pitch a mirage

After all of this, here is what we have: a sensor list, prototype classification figures, claimed training on a large clinical database, planned studies, and commercial headlines with undisclosed terms. Here is what we still do not have: the complete production-device results substantiating the sweeping hormone promise that started this investigation. The sales pitch has arrived. Its central proof has not.

That is why I call the pitch a mirage. Clair asks us to accept a collection of claims and credentials as if the product question were already settled. It is not settled by the material presented here. Explaining why a bracelet could work is much easier than showing how well this one does. Clair keeps asking the explanation to do both jobs.

The answer is a production-device study. Publish the protocol, reference assays, participant counts, separation of training and testing, errors for every promised output, and failures. Then disclose the terms behind the commercial claims. These are the particulars the pitch should have come with.

We have heard what a breakthrough would mean. Show us that this is one.

Preorders are not proof

The same deck claims more than 23,000 people on a waitlist and more than 5,600 preorders. Those are measures of demand for the promise. They do not tell us the bracelet can keep it. Counting preorders is not a clever alternative to testing the product.

The preorder slide blacks out the represented monetary value and supplies no payment, refund, or cancellation terms. Multiplying the count by a price found somewhere else would manufacture a revenue figure the slide does not disclose. Clair can provide the accounting: what was paid, what can be refunded, and what can be cancelled.

The queue may be real. It still cannot validate the bracelet.

The investors financed the pitch. They did not settle the question.

Clair’s transaction counsel confirms an $11.6 million seed led by Khosla. Reach separately identifies itself and a16z speedrun as pre-seed co-leads. The financing is real. Congratulations. Now show us the product results the money does not establish.

The funding breakdown follows the early investor’s account, the claims backers promoted, and the overlap between the adviser and investor networks. It explains how credibility accumulated around Clair. It does not supply the missing product results. More names on the same story do not make the story a clinical trial.

Somebody else’s investment is supposed to reassure me. I would find the evidence behind that confidence considerably more reassuring. Publish it.

Follow the money and the investor claims →